Nevertheless, compared with the PARP inhibitor alone, both of the combinations showed significantly improved efficacy.54 The phase II trial combining an ATR inhibitor (AZD6738) with a PARP inhibitor (olaparib) to treat recurrent ovarian cancers is ongoing (CAPRI: NCT 03462342). Here, PARP1 is linked to ovarian cancer.